Pranlukast

Bezeichnung:Pranlukast

CAS-Nr103177-37-3

Englisch Name:Pranlukast

CBNumberCB3271355

SummenformelC27H23N5O4

Molgewicht481.5

MOL-Datei103177-37-3.mol

Pranlukast physikalisch-chemischer Eigenschaften

Schmelzpunkt	236-238°C
Dichte	1.374±0.06 g/cm3(Predicted)
storage temp.	Sealed in dry,Store in freezer, under -20°C
Löslichkeit	Soluble in DMSO (up to 25 mg/ml)
Aggregatzustand	solid
pka	4.96±0.10(Predicted)
Farbe	White
Merck	14,7710
Stabilität	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
CAS Datenbank	103177-37-3(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher	F,C
R-Sätze:	11-34
S-Sätze:	16-26-36/37/39-45
RTECS-Nr.	CV5647500
HS Code	2934.99.4400
Toxizität	LD50 in male mice (mg/kg): >1000 i.v. (Toda)

Gefahreninformationscode (GHS)

Pranlukast Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R11:Leichtentzündlich.
R34:Verursacht Verätzungen.
S-Sätze Betriebsanweisung:
S16:Von Zündquellen fernhalten - Nicht rauchen.
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
Beschreibung
Pranlukast, a novel chromone derivative, was introduced in Japan for the treatment of bronchial asthma and allergic diseases. Pranlukast is a highly potent, selective and competitive antagonist of peptidoleukotrienes with high affinity for the LTD₄ receptor. In patients with bronchial asthma, pranlukast was reported to induce significant improvement in both immediate and late asthmatic response induced by antigen. Pranlukast is also being evaluated clinically for the treatment of perennial allergic rhinitis, pediatric asthma, and cutaneous pruritus in dialysis patients. The therapeutic potential of pranlukast in managing irritable bowel syndrome has been suggested.
Chemische Eigenschaften
Off-white solid
Originator
Ono (Japan)
Verwenden
antiasthmatic;leukotriene receptor-1 antagonist
Verwenden
A potent, selective and orally active CysLT receptor antagonist. Leukotriene antagonist. Used as an antiasthmatic
Verwenden
Labeled Pranlukast, intended for use as an internal standard for the quantification of Pranlukast by GC- or LC-mass spectrometry.
Definition
ChEBI: N-[4-oxo-2-(2H-tetrazol-5-yl)-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide is a member of chromones.
Trademarks
Onon
Biologische Aktivität
Selective cysteinyl leukotriene receptor 1 (CysLT 1 ) antagonist (IC 50 values are ~ 4-7 and 3620 nM for CysLT 1 and CysLT 2 respectively). Inhibits contraction of airway smooth muscle, microvascular leakage into airways and eosinophil infiltration. Can decrease symptoms of bronchial asthma.
Einzelnachweise
1) Nakai?et al. (1988),?New Potent Antagonists of Leukotrienes C4 and D4. 1. Synthesis and Structure-Activity Relationships; J. Med. Chem.?31?84 2) Taniguchi?et al.?(1993),?The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects; J. Allergy Clin. Immunol.?92?507 3) Ciana?et al.?(2006),?The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor; EMBO J.?25?4615 4) Hennen?et al. (2013),?Decoding Signaling and Function of the Orphan G Protein-Coupled Receptor GPR17 with a Small-Molecule Agonist; Sci. Signal.?6?ra93

Pranlukast Upstream-Materialien And Downstream Produkte

Pranlukast Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

103177-37-3, Pranlukast Verwandte Suche:

Send Inquriy